Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica

Sarah Coseo, Carolina Porras, Allan Hildesheim, Ana Cecilia Rodriguez, Mark Schiffman, Rolando Herrero, Sholom Wacholder, Paula Gonzalez, Sophia S. Wang, Mark E. Sherman, Silvia Jimenez, Diane Solomon, Catherine Bougelet, Leen Jan Van Doorn, Wim Quint, Mahboobeh Safaeian

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Serological indicators of human papillomavirus (HPV) infection are being used to differentiate HPV-naïve from previously infected women in vaccine and epidemiologic/clinical studies. We investigated HPV16 and 18 seroepidemiology among young, unvaccinated women aged between 18 and 25. MATERIALS AND Methods: We conducted a cross-sectional evaluation of the enrollment visit in the ongoing community-based HPV16/18 Costa Rica Vaccine Trial. Prevaccination serum immunoglobulin G (IgG) antibodies were measured against HPV16 and HPV18 by enzyme-linked immunosorbent assay; cervical samples were tested for HPV DNA using Hybrid Capture 2 and SPF10/LiPA25. Seroprevalence and its correlates were evaluated using unconditional logistic regression. Results: Among 5871 nonvirginal women, HPV16 and 18 seroprevalences were 30.8% and 28.1%, HPV16 and HPV18 DNA prevalences were 8.3% and 3.2%, respectively. About 37% of HPV16 DNA-positives and 42% of HPV18 DNA-positives were seronegative. Seroprevalence increased with time since sexual debut, whereas DNA prevalence did not. The correlates of HPV16 and/or 18 seropositivity were related to sexual behaviors, particularly higher number of lifetime sexual partners. There was no evidence of assay cross-reactivity as HPV16 seroprevalence was similar (approximately 34%) among women singly infected with genetically and nongenetically related species (α9 and non-α9); likewise, seropositivity to HPV18 was similar (approximately 30%) among women singly infected with α7 and non-α7 species. Conclusions: The increasing seroprevalence observed with time since first sex suggests that HPV serology is a cumulative marker of HPV exposure. However, many DNA infected women were seronegative; thus, serology is an imperfect measure of past exposure to cervical HPV, at best. Additionally, we found no evidence of assay cross-reactivity.

Original languageEnglish (US)
Pages (from-to)706-714
Number of pages9
JournalSexually Transmitted Diseases
Volume37
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Costa Rica
Human papillomavirus 18
Human papillomavirus 16
Seroepidemiologic Studies
DNA
Serology
Vaccines
Papillomavirus Infections
Sexual Partners
Sexual Behavior
Epidemiologic Studies
Immunoglobulin G
Logistic Models
Enzyme-Linked Immunosorbent Assay
Antibodies
Serum

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Coseo, S., Porras, C., Hildesheim, A., Rodriguez, A. C., Schiffman, M., Herrero, R., ... Safaeian, M. (2010). Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. Sexually Transmitted Diseases, 37(11), 706-714. https://doi.org/10.1097/OLQ.0b013e3181e1a2c5

Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. / Coseo, Sarah; Porras, Carolina; Hildesheim, Allan; Rodriguez, Ana Cecilia; Schiffman, Mark; Herrero, Rolando; Wacholder, Sholom; Gonzalez, Paula; Wang, Sophia S.; Sherman, Mark E.; Jimenez, Silvia; Solomon, Diane; Bougelet, Catherine; Van Doorn, Leen Jan; Quint, Wim; Safaeian, Mahboobeh.

In: Sexually Transmitted Diseases, Vol. 37, No. 11, 11.2010, p. 706-714.

Research output: Contribution to journalArticle

Coseo, S, Porras, C, Hildesheim, A, Rodriguez, AC, Schiffman, M, Herrero, R, Wacholder, S, Gonzalez, P, Wang, SS, Sherman, ME, Jimenez, S, Solomon, D, Bougelet, C, Van Doorn, LJ, Quint, W & Safaeian, M 2010, 'Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica', Sexually Transmitted Diseases, vol. 37, no. 11, pp. 706-714. https://doi.org/10.1097/OLQ.0b013e3181e1a2c5
Coseo, Sarah ; Porras, Carolina ; Hildesheim, Allan ; Rodriguez, Ana Cecilia ; Schiffman, Mark ; Herrero, Rolando ; Wacholder, Sholom ; Gonzalez, Paula ; Wang, Sophia S. ; Sherman, Mark E. ; Jimenez, Silvia ; Solomon, Diane ; Bougelet, Catherine ; Van Doorn, Leen Jan ; Quint, Wim ; Safaeian, Mahboobeh. / Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. In: Sexually Transmitted Diseases. 2010 ; Vol. 37, No. 11. pp. 706-714.
@article{76136496679c45c4b197510aa86267cb,
title = "Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica",
abstract = "Background: Serological indicators of human papillomavirus (HPV) infection are being used to differentiate HPV-na{\"i}ve from previously infected women in vaccine and epidemiologic/clinical studies. We investigated HPV16 and 18 seroepidemiology among young, unvaccinated women aged between 18 and 25. MATERIALS AND Methods: We conducted a cross-sectional evaluation of the enrollment visit in the ongoing community-based HPV16/18 Costa Rica Vaccine Trial. Prevaccination serum immunoglobulin G (IgG) antibodies were measured against HPV16 and HPV18 by enzyme-linked immunosorbent assay; cervical samples were tested for HPV DNA using Hybrid Capture 2 and SPF10/LiPA25. Seroprevalence and its correlates were evaluated using unconditional logistic regression. Results: Among 5871 nonvirginal women, HPV16 and 18 seroprevalences were 30.8{\%} and 28.1{\%}, HPV16 and HPV18 DNA prevalences were 8.3{\%} and 3.2{\%}, respectively. About 37{\%} of HPV16 DNA-positives and 42{\%} of HPV18 DNA-positives were seronegative. Seroprevalence increased with time since sexual debut, whereas DNA prevalence did not. The correlates of HPV16 and/or 18 seropositivity were related to sexual behaviors, particularly higher number of lifetime sexual partners. There was no evidence of assay cross-reactivity as HPV16 seroprevalence was similar (approximately 34{\%}) among women singly infected with genetically and nongenetically related species (α9 and non-α9); likewise, seropositivity to HPV18 was similar (approximately 30{\%}) among women singly infected with α7 and non-α7 species. Conclusions: The increasing seroprevalence observed with time since first sex suggests that HPV serology is a cumulative marker of HPV exposure. However, many DNA infected women were seronegative; thus, serology is an imperfect measure of past exposure to cervical HPV, at best. Additionally, we found no evidence of assay cross-reactivity.",
author = "Sarah Coseo and Carolina Porras and Allan Hildesheim and Rodriguez, {Ana Cecilia} and Mark Schiffman and Rolando Herrero and Sholom Wacholder and Paula Gonzalez and Wang, {Sophia S.} and Sherman, {Mark E.} and Silvia Jimenez and Diane Solomon and Catherine Bougelet and {Van Doorn}, {Leen Jan} and Wim Quint and Mahboobeh Safaeian",
year = "2010",
month = "11",
doi = "10.1097/OLQ.0b013e3181e1a2c5",
language = "English (US)",
volume = "37",
pages = "706--714",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica

AU - Coseo, Sarah

AU - Porras, Carolina

AU - Hildesheim, Allan

AU - Rodriguez, Ana Cecilia

AU - Schiffman, Mark

AU - Herrero, Rolando

AU - Wacholder, Sholom

AU - Gonzalez, Paula

AU - Wang, Sophia S.

AU - Sherman, Mark E.

AU - Jimenez, Silvia

AU - Solomon, Diane

AU - Bougelet, Catherine

AU - Van Doorn, Leen Jan

AU - Quint, Wim

AU - Safaeian, Mahboobeh

PY - 2010/11

Y1 - 2010/11

N2 - Background: Serological indicators of human papillomavirus (HPV) infection are being used to differentiate HPV-naïve from previously infected women in vaccine and epidemiologic/clinical studies. We investigated HPV16 and 18 seroepidemiology among young, unvaccinated women aged between 18 and 25. MATERIALS AND Methods: We conducted a cross-sectional evaluation of the enrollment visit in the ongoing community-based HPV16/18 Costa Rica Vaccine Trial. Prevaccination serum immunoglobulin G (IgG) antibodies were measured against HPV16 and HPV18 by enzyme-linked immunosorbent assay; cervical samples were tested for HPV DNA using Hybrid Capture 2 and SPF10/LiPA25. Seroprevalence and its correlates were evaluated using unconditional logistic regression. Results: Among 5871 nonvirginal women, HPV16 and 18 seroprevalences were 30.8% and 28.1%, HPV16 and HPV18 DNA prevalences were 8.3% and 3.2%, respectively. About 37% of HPV16 DNA-positives and 42% of HPV18 DNA-positives were seronegative. Seroprevalence increased with time since sexual debut, whereas DNA prevalence did not. The correlates of HPV16 and/or 18 seropositivity were related to sexual behaviors, particularly higher number of lifetime sexual partners. There was no evidence of assay cross-reactivity as HPV16 seroprevalence was similar (approximately 34%) among women singly infected with genetically and nongenetically related species (α9 and non-α9); likewise, seropositivity to HPV18 was similar (approximately 30%) among women singly infected with α7 and non-α7 species. Conclusions: The increasing seroprevalence observed with time since first sex suggests that HPV serology is a cumulative marker of HPV exposure. However, many DNA infected women were seronegative; thus, serology is an imperfect measure of past exposure to cervical HPV, at best. Additionally, we found no evidence of assay cross-reactivity.

AB - Background: Serological indicators of human papillomavirus (HPV) infection are being used to differentiate HPV-naïve from previously infected women in vaccine and epidemiologic/clinical studies. We investigated HPV16 and 18 seroepidemiology among young, unvaccinated women aged between 18 and 25. MATERIALS AND Methods: We conducted a cross-sectional evaluation of the enrollment visit in the ongoing community-based HPV16/18 Costa Rica Vaccine Trial. Prevaccination serum immunoglobulin G (IgG) antibodies were measured against HPV16 and HPV18 by enzyme-linked immunosorbent assay; cervical samples were tested for HPV DNA using Hybrid Capture 2 and SPF10/LiPA25. Seroprevalence and its correlates were evaluated using unconditional logistic regression. Results: Among 5871 nonvirginal women, HPV16 and 18 seroprevalences were 30.8% and 28.1%, HPV16 and HPV18 DNA prevalences were 8.3% and 3.2%, respectively. About 37% of HPV16 DNA-positives and 42% of HPV18 DNA-positives were seronegative. Seroprevalence increased with time since sexual debut, whereas DNA prevalence did not. The correlates of HPV16 and/or 18 seropositivity were related to sexual behaviors, particularly higher number of lifetime sexual partners. There was no evidence of assay cross-reactivity as HPV16 seroprevalence was similar (approximately 34%) among women singly infected with genetically and nongenetically related species (α9 and non-α9); likewise, seropositivity to HPV18 was similar (approximately 30%) among women singly infected with α7 and non-α7 species. Conclusions: The increasing seroprevalence observed with time since first sex suggests that HPV serology is a cumulative marker of HPV exposure. However, many DNA infected women were seronegative; thus, serology is an imperfect measure of past exposure to cervical HPV, at best. Additionally, we found no evidence of assay cross-reactivity.

UR - http://www.scopus.com/inward/record.url?scp=78149284252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149284252&partnerID=8YFLogxK

U2 - 10.1097/OLQ.0b013e3181e1a2c5

DO - 10.1097/OLQ.0b013e3181e1a2c5

M3 - Article

C2 - 20661178

AN - SCOPUS:78149284252

VL - 37

SP - 706

EP - 714

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 11

ER -